Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Daiichi Sankyo Co., Ltd. Stock Deutsche Boerse AG

Equities

D4S

JP3475350009

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 04:05:18 2024-04-19 am EDT 		5-day change 1st Jan Change
28.61 EUR +5.42% Intraday chart for Daiichi Sankyo Co., Ltd. -0.80% +17.30%
Apr. 19 Middle East Tensions Dent Asian Stock Markets MT
Apr. 10 Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark MT

Financials

Sales 2024 * 1,580B 10.21B 9.59B Sales 2025 * 1,757B 11.36B 10.66B Capitalization 8,889B 57.46B 53.95B
Net income 2024 * 168B 1.09B 1.02B Net income 2025 * 192B 1.24B 1.17B EV / Sales 2024 * 5.27 x
Net cash position 2024 * 556B 3.59B 3.37B Net cash position 2025 * 599B 3.87B 3.64B EV / Sales 2025 * 4.72 x
P/E ratio 2024 *
53.1 x
P/E ratio 2025 *
46.3 x
Employees 17,435
Yield 2024 *
0.98%
Yield 2025 *
1.14%
Free-Float 97.04%
More Fundamentals * Assessed data

Chart Daiichi Sankyo Co., Ltd.

Dynamic Chart

Latest news about Daiichi Sankyo Co., Ltd.

Middle East Tensions Dent Asian Stock Markets MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication MT
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu MT
AstraZeneca: US approval extended for Enhertu CF
AstraZeneca hails neurological data for Ultomiris, Soliris AN
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval MT
Astra hails neurology data; CVS flags cyberattack AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval AN
AstraZeneca Wins US Approval for Solid Tumor Treatment MT
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors RE
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer MT
Merck: 1st patient in raludotatug study CF
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer CI
More news

Latest transcript on Daiichi Sankyo Co., Ltd.

Logo Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited - Special Call
More transcripts

Analyst Recommendations on Daiichi Sankyo Co., Ltd.

Jefferies Adjusts Daiichi Sankyo’s Price Target to 5,600 Yen From 4,800 Yen, Keeps at Buy MT
Berenberg: AstraZeneca Set for More Lung Cancer Success After Recent Pipeline Gains MT
Japan's Nikkei slips after Fed chair signals delay in rate cut RE
Jefferies Upgrades Daiichi Sankyo to Buy From Hold, Adjusts Price Target to 4,800 Yen From 4,300 Yen MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 4,300 Yen From 3,900 Yen, Keeps at Hold MT
More recommendations

Press releases Daiichi Sankyo Co., Ltd.

Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours AQ
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB PU
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer AQ
Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB PU
Daiichi Sankyo : Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer(204.8KB PU
More press releases

News in other languages on Daiichi Sankyo Co., Ltd.

Roche erhält CE-Kennung für erstes Brustkrebs-Begleitdiagnostikum
Scholz setzt auf weitere Pharma-Investitionen in Deutschland
AstraZeneca : approbation étendue pour Enhertu aux USA
Les valeurs à suivre à Paris et en Europe (actualisé)
Un séisme de magnitude 6,0 secoue le nord-est du Japon, pas d'alerte au tsunami
More news

Quotes and Performance

1 day+5.42%
1 week-0.80%
Current month-3.96%
1 month-2.92%
3 months+7.72%
6 months+28.01%
Current year+17.30%
More quotes

Highs and lows

1 week
26.61
Extreme 26.61
28.61
1 month
26.61
Extreme 26.61
30.45
Current year
24.46
Extreme 24.46
33.13
1 year
22.35
Extreme 22.35
34.48
3 years
15.05
Extreme 15.05
34.80
5 years
13.40
Extreme 13.3983
34.80
10 years
3.72
Extreme 3.717
34.80
More quotes

Managers and Directors - Daiichi Sankyo Co., Ltd.

Managers TitleAgeSince
Sunao Manabe CEO
 Chief Executive Officer 69 07-03-31
Hiroyuki Okuzawa PSD
 President 61 17-03-31
Ken Takeshita CTO
 Chief Tech/Sci/R&D Officer - 21-03-31
Members of the board TitleAgeSince
Sawako Nohara BRD
 Director/Board Member 66 19-05-31
Kazuaki Kama BRD
 Director/Board Member 75 19-05-31
Sunao Manabe CEO
 Chief Executive Officer 69 07-03-31
More insiders

Quotes

Date Price Change Volume
24-04-19 28.61 +5.42% 356
24-04-18 27.14 -0.22% 0
24-04-17 27.2 -0.37% 88
24-04-16 27.3 -0.26% 0
24-04-15 27.37 -5.10% 0

Delayed Quote Deutsche Boerse AG, April 19, 2024 at 04:05 am EDT

More quotes

Company Profile

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24 - Q4 2024 Earnings Release
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,636 JPY
Average target price
5,620 JPY
Spread / Average Target
+21.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 203B
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock